MLTX Valuation

MoonLake Immunotherapeutics

Add to Watchlist

Advanced Chart

10.200

+0.1(0.990%)1D

MLTX Relative Valuation

MLTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MLTX is overvalued; if below, it's undervalued.

Historical Valuation

MoonLake Immunotherapeutics (MLTX) is now in the Fair zone, suggesting that its current forward PS ratio of 10.10 is considered Fairly compared with the five-year average of -20.80. The fair price of MoonLake Immunotherapeutics (MLTX) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：10.10

Fair

-2.93

Trailing

Forward

-1.12

EV/EBITDA

MoonLake Immunotherapeutics. (MLTX) has a current EV/EBITDA of -1.12. The 5-year average EV/EBITDA is -15.16. The thresholds are as follows: Strongly Undervalued below -35.18, Undervalued between -35.18 and -25.17, Fairly Valued between -5.15 and -25.17, Overvalued between -5.15 and 4.87, and Strongly Overvalued above 4.87. The current Forward EV/EBITDA of -1.12 falls within the Overvalued range.

-1.06

EV/EBIT

MoonLake Immunotherapeutics. (MLTX) has a current EV/EBIT of -1.06. The 5-year average EV/EBIT is -15.73. The thresholds are as follows: Strongly Undervalued below -38.04, Undervalued between -38.04 and -26.89, Fairly Valued between -4.58 and -26.89, Overvalued between -4.58 and 6.57, and Strongly Overvalued above 6.57. The current Forward EV/EBIT of -1.06 falls within the Overvalued range.

10.10

MoonLake Immunotherapeutics. (MLTX) has a current PS of 10.10. The 5-year average PS is 0.04. The thresholds are as follows: Strongly Undervalued below -1.22, Undervalued between -1.22 and -0.59, Fairly Valued between 0.67 and -0.59, Overvalued between 0.67 and 1.30, and Strongly Overvalued above 1.30. The current Forward PS of 10.10 falls within the Strongly Overvalued range.

-2.66

P/OCF

MoonLake Immunotherapeutics. (MLTX) has a current P/OCF of -2.66. The 5-year average P/OCF is -21.27. The thresholds are as follows: Strongly Undervalued below -48.58, Undervalued between -48.58 and -34.93, Fairly Valued between -7.62 and -34.93, Overvalued between -7.62 and 6.04, and Strongly Overvalued above 6.04. The current Forward P/OCF of -2.66 falls within the Overvalued range.

-2.77

P/FCF

MoonLake Immunotherapeutics. (MLTX) has a current P/FCF of -2.77. The 5-year average P/FCF is -20.19. The thresholds are as follows: Strongly Undervalued below -45.07, Undervalued between -45.07 and -32.63, Fairly Valued between -7.75 and -32.63, Overvalued between -7.75 and 4.69, and Strongly Overvalued above 4.69. The current Forward P/FCF of -2.77 falls within the Overvalued range.

MoonLake Immunotherapeutics (MLTX) has a current Price-to-Book (P/B) ratio of 1.81. Compared to its 3-year average P/B ratio of 8.33 , the current P/B ratio is approximately -78.24% higher. Relative to its 5-year average P/B ratio of 6.93, the current P/B ratio is about -73.85% higher. MoonLake Immunotherapeutics (MLTX) has a Forward Free Cash Flow (FCF) yield of approximately -0.27%. Compared to its 3-year average FCF yield of -4.90%, the current FCF yield is approximately -94.55% lower. Relative to its 5-year average FCF yield of -7.40% , the current FCF yield is about -96.39% lower.

1.81

P/B

Median3y

8.33

Median5y

6.93

-0.27

FCF Yield

Median3y

-4.90

Median5y

-7.40

Competitors Valuation Multiple

The average P/S ratio for MLTX's competitors is 8.08, providing a benchmark for relative valuation. MoonLake Immunotherapeutics Corp (MLTX) exhibits a P/S ratio of 10.10, which is 24.97% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

MLTX.O

MoonLake Immunotherapeutics

Emergent BioSolutions Inc

Compass Therapeutics Inc.

Olema Pharmaceuticals Inc

Performance Decomposition

Market capitalization of MLTX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of MLTX in the past 1 year is driven by Unknown.